Prenetics Reports Record Q1 2026 Results and Raises Annual Revenue Guidance

Prenetics reported record preliminary financial results for the first quarter of 2026, highlighted by total revenue of $36.0 million. This performance was primarily driven by the IM8 unit, which saw its revenue grow nearly sixfold compared to the previous year. Additionally, the company executed a strategic divestment of its entire digital asset portfolio, generating $41.3 million in proceeds to bolster its cash reserves.

This shift toward core profitability occurs as the biotech and supplement sectors face mixed market conditions; for context, global economic indicators such as Germany's trade balance reached 14.3 billion in May 2026 per market data. The decision to exit digital assets reflects management's commitment to core operations and mitigating the balance sheet volatility that impacted several industry peers during the previous fiscal year.

Looking ahead, Prenetics has raised its full-year 2026 revenue guidance for the IM8 unit to a range of $190 million to $210 million. Investors are closely monitoring the deployment of the newly acquired cash from asset sales as a primary growth catalyst. On the macro front, market participants are eyeing upcoming Chinese inflation data in mid-May, which could impact global supply chain costs for the firm's manufacturing operations.